Russia's Pharmsynthez raises $17 million in IPO in Moscow
This article was originally published in Scrip
Executive Summary
Russia's Pharmsynthez has raised Rb528 million ($17 million) in an IPO conducted on the market for innovations and investments of Moscow Interbank Currency Exchange (MICEX). On 1 December, the shares also began trading under the same LIFE ticker without an additional listing on the Russian Trading System Stock Exchange (RTS).
You may also be interested in...
Poland's new law fixes prices and trade mark-ups of reimbursed drugs
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
Global pharma boosts business in Russia - Why Russia (introduction)
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Medvedev wants talks on trials mutual recognition with US and EU
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.